Valdés-Delgado, Teresa
Aguado-Paredes, Alicia
Merino-Bohórquez, Vicente
Martín-Manzanares, Jesús
Alonso, María Mercedes
Maldonado, Belén
Castro, Luisa
Belvis, María
Benítez, Beatriz
Caunedo, Ángel
Calleja, Miguel Ángel
Argüelles-Arias, Federico http://orcid.org/0000-0003-3646-8919
Funding for this research was provided by:
Grifols
Universidad de Sevilla
Article History
Received: 31 May 2023
Accepted: 24 August 2023
First Online: 9 November 2023
Declarations
:
: F. Argüelles-Arias, B. Maldonado, L. Castro, M. Belvis, B. Benítez, and Á. Caunedo, have served as speaker, consultant, and advisory member for, or has received research funding from: MSD, Abbvie, Pfizer, Kern Pharma, Takeda, Janssen, Ferring, Faes Farma, Shire Pharmaceuticals, Tillotts Pharma, Galápagos and Chiesi. T. Valdés-Delgado has served as speaker, consultant, and advisory member for, or has received research funding from: Janssen, Tillotts Pharma, and Galapagos. V. Merino-Bohórquez has served as speaker, consultant, and advisory member for, or has received research funding from: Janssen, Abbvie, Kern Pharma, Pfizer, Sandoz, Novartis, and Galapagos. J. Martín-Manzanares, M.M. Alonso, A. Aguado-Paredes, and M.A. Calleja have no conflict of interest.
: The study protocol was reviewed and approved by the Institutional Review board/ Independent Ethics Committee of Research with Medicines (CEIm) Provincial of Seville. All patients signed the written informed consent before study initiation.